SEC Form 4 · accession 0001209191-16-095841
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 6:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2016 | A | 14,416 | $0.01 | A | 114,978 | D | |
| Common StockF3,F4 | Feb 2, 2016 | S | 1,100 | $90.89 | D | 113,878 | D | |
| Common StockF3,F5 | Feb 2, 2016 | S | 1,275 | $91.80 | D | 112,603 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF6 | $91.05 | Feb 2, 2016 | A | 28,735 | A | — | Feb 1, 2026 | Common Stock | 28,735 | 28,735 | D |
Explanation of responses
- F1Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
- F2Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $90.89 (range $90.49 to $91.33).
- F5Open market sales reported on this line occurred at a weighted average price of $91.80 (range $91.56 to $92.36).
- F6The option vests in 16 quarterly installments from 02/02/2016.